ReviewInnere Medizin (Heidelberg, Germany)2026
[Update on hypertrophic cardiomyopathy].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Europe, the term 'hypertrophic cardiomyopathy' (HCM) encompasses both primary, genetic forms and secondary, acquired forms. If echocardiography confirms wall thickening of the left ventricle without a clear connection to pathological stress conditions, a targeted differential diagnosis should be performed. Cardiac magnetic resonance imaging plays a key role in definitive diagnosis. Genetic testing should also be considered for many forms of HCM, especially for the common primary HCM. Stratification with regard to arrhythmia risk is mandatory for all patients with primary HCM. Symptomatic treatment is available, particularly in cases of relevant obstruction of the left ventricular outflow tract, in the form of catheter ablation or pharmacotherapy with myosin inhibitors. Transthyretin amyloid cardiomyopathy, the most common secondary form, can be treated specifically after exclusion of amyloid light-chain amyloidosis.
Indexed as
Identifiers
41770327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.